A phase I clinical trial has confirmed the safe uptake of an unconjugated humanized FAP monoclonal blocking antibody (sibrotuzumab) to target FAP+ fibroblasts in colorectal carcinoma and non-small cell lung cancer, although there was very little tumor response and the antibody has not progressed in the clinic [308]. This evidence concerns the gene FAP and colorectal carcinoma.